Skip to main content
. 2021 Nov 13;12(11):1079. doi: 10.1038/s41419-021-04367-3

Fig. 5. Cetuximab enhances the inhibitory effects of RSL3 and RSL3-induced ferroptosis in vivo.

Fig. 5

A Schematic of the anticancer effect of the combination of RSL3 (5 mg/kg) and cetuximab (13 mg/kg) in a DLD-1 cell subcutaneous tumour model. B The tumour weights of excised tumours on day 19. C Excised tumours on day 19. D The tumour volume of each group was calculated every 3 days. E The body weight of each group was calculated every 3 days. F The level of MDA in excised tumours on day 19 was assayed. **P < 0.01.